SITE001-0140

completed

A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE001 (USA) · Dr. Reyes

consented 2022-08-06

AEs
3
Serious
0
Dropout signal

Adverse events

mild assessed

Grade 1 Constipation — outcome: RECOVERED/RESOLVED; onset 2023-09-11 (study day 385); relationship: not assessed

mild assessed

Grade 1 Peripheral neuropathy — outcome: RECOVERED/RESOLVED; onset 2023-12-07 (study day 472); relationship: not assessed

severe assessed

Grade 3 Vomiting — outcome: RECOVERED/RESOLVED; onset 2024-02-28 (study day 555); relationship: not assessed

Data queries

No data queries.